Kim, Sindher, Huffaker spoke with HCPLive about some of the year’s most important developments in the food allergy space, namely the approvals of omalizumab and neffy.
Michelle Huffaker, MD
Advertisement
Michelle Huffaker, MD, is the director of Clinical Translational Medicine in the Allergy Portfolio at the Immune Tolerance Network and a practicing allergist.
Articles by Michelle Huffaker, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Sebetralstat Shows QoL Gains on Top of HAE Prophylaxis in KONFIDENT-S
2
The HCPFive: Top News for Healthcare Providers from the Week of 07/19
3
Can We Stop Heart Failure at Its Source?
4
Sanofi Announces Discontinuation of Amlitelimab for Atopic Dermatitis
5